Results of treatment of chronic hepatitis B with pegylated interferon

Mauro Viganò, Giampaolo Mangia, Pietro Lampertico

Research output: Contribution to journalArticlepeer-review


Persistent viral eradication or suppression through a defined course of Pegylated-interferon (PegIFN) or the administration of a long-term potent nucleot(s)ide analogues (NUCs) can impact positively the natural course of HBV infection by preventing disease progression. Despite the higher rates of off-therapy response achieved with PegIFN compared with NUC, its benefits are restricted to a subgroup of patients only. To increase the rates of patients who may benefit from PegIFN treatment, minimizing the adverse events, careful patient selections based on baseline features and on treatment HBsAg kinetics for individual treatment optimization are required.

Original languageEnglish
Pages (from-to)425-443
Number of pages19
JournalClinics in Liver Disease
Issue number3
Publication statusPublished - Aug 2013


  • Chronic hepatitis B
  • HBsAg levels
  • IL28B polymorphism
  • Pegylated interferon
  • Sustained response

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Results of treatment of chronic hepatitis B with pegylated interferon'. Together they form a unique fingerprint.

Cite this